1. Home
  2. ALLO vs JMSB Comparison

ALLO vs JMSB Comparison

Compare ALLO & JMSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • JMSB
  • Stock Information
  • Founded
  • ALLO 2017
  • JMSB 2005
  • Country
  • ALLO United States
  • JMSB United States
  • Employees
  • ALLO N/A
  • JMSB N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • JMSB Major Banks
  • Sector
  • ALLO Health Care
  • JMSB Finance
  • Exchange
  • ALLO Nasdaq
  • JMSB Nasdaq
  • Market Cap
  • ALLO 252.9M
  • JMSB 276.5M
  • IPO Year
  • ALLO 2018
  • JMSB N/A
  • Fundamental
  • Price
  • ALLO $1.21
  • JMSB $19.57
  • Analyst Decision
  • ALLO Buy
  • JMSB Buy
  • Analyst Count
  • ALLO 12
  • JMSB 2
  • Target Price
  • ALLO $8.80
  • JMSB $22.50
  • AVG Volume (30 Days)
  • ALLO 2.9M
  • JMSB 14.9K
  • Earning Date
  • ALLO 11-13-2025
  • JMSB 10-23-2025
  • Dividend Yield
  • ALLO N/A
  • JMSB 1.55%
  • EPS Growth
  • ALLO N/A
  • JMSB 688.28
  • EPS
  • ALLO N/A
  • JMSB 1.32
  • Revenue
  • ALLO N/A
  • JMSB $56,750,000.00
  • Revenue This Year
  • ALLO N/A
  • JMSB $18.55
  • Revenue Next Year
  • ALLO $100.00
  • JMSB $13.30
  • P/E Ratio
  • ALLO N/A
  • JMSB $14.83
  • Revenue Growth
  • ALLO N/A
  • JMSB 59.00
  • 52 Week Low
  • ALLO $0.86
  • JMSB $13.81
  • 52 Week High
  • ALLO $3.78
  • JMSB $26.52
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 49.04
  • JMSB 51.41
  • Support Level
  • ALLO $1.21
  • JMSB $18.90
  • Resistance Level
  • ALLO $1.26
  • JMSB $20.02
  • Average True Range (ATR)
  • ALLO 0.08
  • JMSB 0.52
  • MACD
  • ALLO -0.01
  • JMSB 0.03
  • Stochastic Oscillator
  • ALLO 14.18
  • JMSB 68.09

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About JMSB John Marshall Bancorp Inc.

John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.

Share on Social Networks: